Table 4.
Characteristics and treatment details of patients with AIH variants
| Patient | Diagnosis | Age, gender | Reason for prior AZA/MP failure | Tioguanine therapy | Biochemical response | Drug survival | Prednisone | Comedication | ||
|---|---|---|---|---|---|---|---|---|---|---|
| mg/d | Mo | Baseline (mg/d) | Last FU (mg/d) | |||||||
| 1 | AIH‐PSC | 17, m | Nonresponse, AZA/MP | 21 | 3 | Nonresponse | No | 20 | 20 | UDCA (14 mg/kg) |
| 2 | AIH‐PSC | 40, f | Nonresponse, AZA | 21 | 31 | Incomplete | Yes | 10 | 7.5 | UDCA (12 mg/kg, tacrolimus |
| 3 | AIH‐PSC | 40, f | Nonresponse, AZA/MP | 24 | 97 | Incomplete | Noa | 10 | 2.5 | UDCA (14 mg/kg) |
| 4 | AIH‐PSC | 51, m | Nonresponse and intolerance, AZA | 20 | 11 | Complete | Intolerant | 30 | 5 | UDCA (24 mg/kg) |
| 5 | AIH‐PSC | 67, m | Intolerance, AZA | 10 | 3 | Incomplete | Yes | 10 | — | — |
| 6 | AIH‐PSC | 29, m | Intolerance, AZA | 20 | 5 | Complete | Yes | — | 10 | UDCA (13 mg/kg) |
| 7 | AIH‐PBC | 67, f | Nonresponse and intolerance, MP | 20 | 86 | Complete | Yes | 30 | 10 | UDCA (13 mg/kg), ciclosporin |
| 8 | AIH‐PBC | 67, f | Intolerance, AZA | 20 | 93 | Complete | Yes | — | — | UDCA (18 mg/kg) |
| 9 | AMA neg. AIH‐PBC | 62, f | Toxic levels and intolerance, AZA/MP | 18 | 18 | Complete | Intolerant | 10 | 10 | UDCA (9 mg/kg), budesonideb |
| 10 | AMA neg. AIH‐PBC | 27, f | Toxic levels, AZA | 24 | 80 | Complete | Noc | 30 | — | UDCA (19 mg/kg) |
AZA: azathioprine; f: female; m: male; MP: mercaptopurine; UDCA: ursodeoxycholic acid.
a
Initially, nodular regenerative hyperplasia was suspected in histology, however, review of the histology by two hepatopathologists did not confirm this.
b
Budesonide (6 mg/d) was fully tapered.
c
A trial of withdrawal was offered after more than 2 years of complete biochemical remission on tioguanine monotherapy, according to recent guidelines.1